Atara Biotherapeutics (ATRA) reported "compliance issues" on Thursday involving a third-party manufacturing facility for Ebvallo, a treatment for patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease.
Shares slumped 37% as intraday trading volume catapulted to over 1.8 million million versus a daily average of about 127,000.
Silexion Therapeutics (SLXN) shares slumped intraday after the company overnight disclosed a $5 million equity offering to fund pre-clinical studies.
Shares plunged 42% as intraday trading volume rose to roughly 6.58 million from the stock's daily average of about 4.63 million.
US Bancorp (USB) shares dropped after the company reported Thursday Q4 revenue that missed expectations.
Shares slid 5%, with intraday trading volume at nearly 11.6 million versus the stock's daily average of over 7.61 million.
Price: 8.29, Change: -4.87, Percent Change: -37.00
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.